Navigation Links
Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
Date:10/5/2007

EMERYVILLE, Calif., Oct. 5 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI), a leader in the discovery and development of safe and effective drugs in the areas of women's health and cancer, today announced that Tom Chesterman, SVP and CFO of Bionovo, Inc., will present at the 4th Annual BIO Investor Forum.

The presentation will take place on October 11, 2007 at 12:30 p.m. PDT at the Palace Hotel in San Francisco, CA.

A live audio web cast and slide presentation of the event will be available via a link at: http://www.bionovo.com.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the Nasdaq Capital Market under the symbol BNVI. For more information about Bionovo and its programs, visit http://www.bionovo.com.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 , Not for release, publication ... from any jurisdiction where to do so would constitute a ... Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: ... confirms it has held a meeting with representatives of AbbVie. ... the prior agreement or approval of AbbVie. A ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Product ... in very low abundance and are often “lost ... and time-consuming. , Join presenters Dr. Rowel Tobias, ... Dr. John Anders, Head of Quality at Nanotherapeutics, ... approach that can speed detection and quantitation while ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Unraveling ... closer together. The Archer Family purchased a ... within DNA, but ended up with a lifetime of ... contained within the family members’ DNA genuinely brought the ... decided to search deeper into genetic history and prior ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... N.J., July 10 Senesco Technologies , Inc. ... announced that, on July 9, 2009, the Company entered into a ... sale of (i) up to 1,111,111 shares of its common stock ... to purchase an aggregate of up to 1,000,000 shares of common ...
... of Energy,s Lawrence Berkeley National Laboratory and the University ... fabricate efficient solar cells from low-cost and flexible materials. ... of nanoscale pillars, each a single crystal, with dimensions ... take advantage of abundant solar energy we have to ...
... July 9 PharmAthene, Inc. (NYSE Amex: ... biological and chemical threats, today announced that the U.S. ... of the Company,s proposed development plan for SparVax(TM), PharmAthene,s ... , In response to amendments to the request ...
Cached Biology Technology:Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 2Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 3Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 4Nanopillars promise cheap, efficient, flexible solar cells 2Nanopillars promise cheap, efficient, flexible solar cells 3PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review 2PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review 3PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review 4
(Date:7/11/2014)... of Standards and Technology (NIST) need a special ... often prove that necessity is truly the mother ... M. Lorna De Leoz and Stephen Stein, NIST ... Glycomics is the study of the abundant, often-branched ... proteins and lipids and influence cellular processes, including ...
(Date:7/11/2014)... 3, 2014, Shenzhen, China Researchers from Salk Institute ... the first time evaluated the safety and reliability ... successfully developed a new method, TALEN-HDAdV, which could ... stem cell (hiPSC). This study published online in ... theoretical foundation for stem cell-based gene therapy. , ...
(Date:7/11/2014)... the Max Planck Institute for Medical Research in Heidelberg, ... photosynthesis, the process by which the Earth first gained ... which is therefore crucial for all higher forms of ... first direct visualization of a crucial event in the ... protein complex, photosystem II, splits water into hydrogen and ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2A first direct glimpse of photosynthesis in action 2
... available in Spanish . Learning more ... used by U.S. Department of Agriculture (USDA) scientists to identify ... bed bugs over the last decade has caused problems in ... and even places of work. The small, blood-feeding insects are ...
... have found that one of the most aggressive invasive ant ... appears to have met its match in the Asian needle ... ant is successfully displacing Argentine ants in an urban environment, ... sting may be the next invasive species to see ...
... MDIf you have an overactive bladder or incontinence, help could be ... FASEB Journal , shows that the epithelium, a ... is able to sense how full the bladder is through the ... bladder becomes full, the cells in the epithelium stretch and become ...
Cached Biology News:Studying bed bug actions for new management tactics 2Researchers find Asian needle ants displacing other aggressive invaders 2Got to go? Harvard scientists figure out how you know 2
... and PowerPac 3000 system, 220-240 V, is used ... 50 cm vertical slab gel format. The system ... is capable of separating nucleic acids with single ... (IPC) assembly (IPC and bonded inner glass plate, ...
... Plus overlay agarose is used for ... IPG strips in place in PROTEAN ... is incorporated to allow monitoring of ... of 0.75% agarose in 1x Tris, ...
... The PowerPac HV high-voltage power supply, with ... increased output of 5,000 V, 500 mA, and ... monitor gel temperature between 0 and 90 degrees ... wireless data transfer. Power cord and instructions are ...
The stirbar is used in the buffer tank of the Trans-Blot Plus cell to maintain uniform conductivity and temperature during electrophoretic transfer. Dimensions are 3.5 x 0.5 in....
Biology Products: